SAN FRANCISCO, March 11, 2021 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will present at the Oppenheimer 31st Annual Healthcare Conference, a virtual event, on Wednesday, March 17, 2021 at 1:10 p.m. ET.
The presentation will be available through the Oppenheimer conference portal and an archived webcast will also be accessible in the investor section of 89bio’s website.
About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com
Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com
Profession Ranks #1 for Best Job, Best Health Care Job and Best STEM Job AUSTIN,…
LAS VEGAS, Jan. 15, 2025 /PRNewswire/ -- Informa Connect announces a landmark collaboration with Behavioral…
DELRAY BEACH, Fla., Jan. 15, 2025 /PRNewswire/ -- The global AI medical imaging market, valued at…
Winning startups across the pet industry – from veterinary care to treats and e-commerce –…
COLCHESTER, Vt., Jan. 15, 2025 /PRNewswire/ -- Leading lab middleware company Data Innovations, LLC, has…
WALTHAM, Mass., Jan. 15, 2025 /PRNewswire/ -- Accelerated Cure Project (ACP) for Multiple Sclerosis (MS)…